DOP2012000316A - Metodo para diagnosticar una respuesta al tratamiento en sujetos con esclerosis multiple - Google Patents

Metodo para diagnosticar una respuesta al tratamiento en sujetos con esclerosis multiple

Info

Publication number
DOP2012000316A
DOP2012000316A DO2012000316A DO2012000316A DOP2012000316A DO P2012000316 A DOP2012000316 A DO P2012000316A DO 2012000316 A DO2012000316 A DO 2012000316A DO 2012000316 A DO2012000316 A DO 2012000316A DO P2012000316 A DOP2012000316 A DO P2012000316A
Authority
DO
Dominican Republic
Prior art keywords
treatment
multiple sclerosis
diagnosing
subjects
subject
Prior art date
Application number
DO2012000316A
Other languages
English (en)
Inventor
Richard A Rudick
Richard M Ransohoff
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000316(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of DOP2012000316A publication Critical patent/DOP2012000316A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee un método para determinar la eficiencia del tratamiento con interferón beta (IFN-ß) en un sujeto con esclerosis múltìple. Unpasodelmétodopuede incluirlaobtencióndeunamuestra biológicatomadadelsujeto. Despuésdeobtenerlamuestrabiológica, puede determinarse el nivel de expresión de al menos un gen regulado por interferón (IRG) y/o su variante. Una expresión aumentada o reducida del al menos un IRG y/o su variante en comparación con un control puede indicar que el sujeto responderá mal a1 tratamiento con interferón beta.
DO2012000316A 2010-06-18 2012-12-18 Metodo para diagnosticar una respuesta al tratamiento en sujetos con esclerosis multiple DOP2012000316A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35626510P 2010-06-18 2010-06-18

Publications (1)

Publication Number Publication Date
DOP2012000316A true DOP2012000316A (es) 2013-07-31

Family

ID=45348885

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000316A DOP2012000316A (es) 2010-06-18 2012-12-18 Metodo para diagnosticar una respuesta al tratamiento en sujetos con esclerosis multiple

Country Status (22)

Country Link
US (1) US20130089519A1 (es)
EP (1) EP2585100A4 (es)
JP (1) JP2013534419A (es)
KR (1) KR20130036046A (es)
CN (1) CN103140235A (es)
AU (1) AU2011268223B2 (es)
BR (1) BR112012032344A2 (es)
CA (1) CA2802999A1 (es)
CL (1) CL2012003571A1 (es)
CO (1) CO6670574A2 (es)
CR (1) CR20130018A (es)
DO (1) DOP2012000316A (es)
EA (1) EA201370003A1 (es)
EC (1) ECSP13012390A (es)
MA (1) MA34381B1 (es)
MX (1) MX2012015028A (es)
NI (1) NI201200188A (es)
PE (1) PE20130645A1 (es)
SG (1) SG186393A1 (es)
TN (1) TN2012000607A1 (es)
WO (1) WO2011159970A2 (es)
ZA (1) ZA201300019B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160265058A1 (en) * 2013-11-01 2016-09-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Diagnostic methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder
BR112018007474A2 (pt) * 2015-10-14 2018-10-30 Novozymes A/S ?limpeza de membranas de filtração de água?
CN108304912B (zh) * 2017-12-29 2020-12-29 北京理工大学 一种运用抑制信号实现脉冲神经网络监督学习的系统和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320606T1 (de) * 2002-05-29 2006-04-15 Charite Universitaetsmedizin Verfahren zur identifizierung von auf ifn-beta ansprechenden multiple sklerose patienten, durch die bestimmung der expression von trail
WO2005108610A2 (en) * 2004-04-05 2005-11-17 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for the selection of subjects for multiple sclerosis therapy
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
EP2009440A1 (en) * 2007-06-01 2008-12-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Means and methods for classifying samples of multiple sclerosis patients.
KR20110073451A (ko) * 2008-09-16 2011-06-29 바이엘 헬스케어 엘엘씨 임상 샘플에서의 인터페론 반응 (ｉｒｉｓ)

Also Published As

Publication number Publication date
AU2011268223A1 (en) 2013-01-31
EA201370003A1 (ru) 2013-06-28
CR20130018A (es) 2013-04-26
KR20130036046A (ko) 2013-04-09
CO6670574A2 (es) 2013-05-15
MA34381B1 (fr) 2013-07-03
WO2011159970A3 (en) 2012-04-19
US20130089519A1 (en) 2013-04-11
AU2011268223B2 (en) 2014-05-29
CA2802999A1 (en) 2011-12-22
WO2011159970A2 (en) 2011-12-22
NI201200188A (es) 2013-04-15
BR112012032344A2 (pt) 2017-05-30
ZA201300019B (en) 2014-03-26
MX2012015028A (es) 2013-06-13
CN103140235A (zh) 2013-06-05
PE20130645A1 (es) 2013-07-03
EP2585100A4 (en) 2013-11-06
SG186393A1 (en) 2013-01-30
ECSP13012390A (es) 2013-04-30
CL2012003571A1 (es) 2013-08-23
EP2585100A2 (en) 2013-05-01
TN2012000607A1 (en) 2014-04-01
JP2013534419A (ja) 2013-09-05

Similar Documents

Publication Publication Date Title
ES2548508T3 (es) Métodos de tratamiento de enfermedades
PE20121690A1 (es) Signatura transcripcional en la sangre de infecciones de mycobacterium tuberculosis activas versus latentes
ES2527776T3 (es) Biomarcadores para predecir la sensibilidad de células a compuestos inmunomoduladores durante el tratamiento del linfoma no Hodgkin
BR112015017767A2 (pt) sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo
TR201902135T4 (tr) Kırılma tahmin yöntemi, hesaplama işlem cihazı, program ve kayıt ortamı.
ES2528321T3 (es) Detección de a-fucosilación en anticuerpos
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
CL2011002959A1 (es) Peptoide, metodo para identificar un ligando peptoide que es especificamente reconocido por las celulas autoinmunes; y su uso contre enfermedades autoinmune.
MX347871B (es) Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
BR112018011224A2 (pt) processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs)
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
DOP2012000316A (es) Metodo para diagnosticar una respuesta al tratamiento en sujetos con esclerosis multiple
GB201201766D0 (en) Method
AR106407A1 (es) Plataforma de pesaje de un animal y proceso de pesaje de un animal
MX2017009752A (es) Adn huesped como biomarcador de la enfermedad de crohn.
CL2011002260A1 (es) Metodo o sistema para el seguimiento del tratamiento de un individuo que comprende determinar si una muestra de dicho individuo comprende un biomarcador.
CL2014000451A1 (es) Metodo para sedar, anestesiar o someter a eutanasia un organismo acuático que comprende poner en contacto dicho organismo con linalol; composición que comprende linalol y al menos un solvente o surfactante.
ES2663596T3 (es) Cepa de algas modificada y método de acumulación de triacilglicerol utilizando dicha cepa
BR112014008311A2 (pt) método de prognóstico para diabetes
CL2018000664A1 (es) Método in vitro para identificar una enfermedad relacionada con el embarazo
UA92113U (uk) Спосіб прогнозування розвитку цукрового діабету 2 типу у хворих на гіпертонічну хворобу за активністю апеліну
Amistad et al. Death Anxiety and Self-Esteem of the Filipino Able-aged
White et al. Understanding The Mechanisms Of Physician-Family Discordance About Prognosis In Icus: Distinguishing Misunderstandings From Disbelief
UA99821U (uk) Спосіб моделювання хронічного іммобілізаційного стресу, підсиленого дією гострого стресу
CL2015000512A1 (es) Método para diagnóstico de cancer